Matthew Luchini
Stock Analyst at BMO Capital
(1.13)
# 3,441
Out of 4,820 analysts
50
Total ratings
32.14%
Success rate
-8.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Luchini
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Maintains: Outperform | $51 → $30 | $9.05 | +231.49% | 4 | Mar 18, 2022 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | $190 | $4.68 | +3,959.83% | 1 | Oct 20, 2021 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $89 → $69 | $17.41 | +296.32% | 3 | Sep 10, 2021 | |
| KOD Kodiak Sciences | Maintains: Market Perform | $138 → $104 | $4.14 | +2,415.11% | 3 | May 11, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | $55 | $1.55 | +3,459.87% | 1 | Mar 31, 2021 | |
| ARVN Arvinas | Initiates: Outperform | $101 | $9.05 | +1,016.02% | 2 | Mar 31, 2021 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $630 | $602.64 | +4.54% | 13 | Jan 25, 2021 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Market Perform | $119 → $124 | $325.27 | -61.88% | 2 | Nov 6, 2020 | |
| BLUE bluebird bio | Downgrades: Market Perform | $1,120 | $4.16 | +26,823.08% | 11 | Nov 5, 2020 | |
| GILD Gilead Sciences | Maintains: Market Perform | $74 → $64 | $103.17 | -37.97% | 2 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $14 | $24.99 | -43.98% | 1 | Jun 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $47 → $60 | $1.47 | +3,981.63% | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $120 → $164 | $2.76 | +5,856.52% | 5 | Mar 8, 2018 |
Replimune Group
Mar 18, 2022
Maintains: Outperform
Price Target: $51 → $30
Current: $9.05
Upside: +231.49%
Jasper Therapeutics
Oct 20, 2021
Initiates: Outperform
Price Target: $190
Current: $4.68
Upside: +3,959.83%
Apellis Pharmaceuticals
Sep 10, 2021
Maintains: Outperform
Price Target: $89 → $69
Current: $17.41
Upside: +296.32%
Kodiak Sciences
May 11, 2021
Maintains: Market Perform
Price Target: $138 → $104
Current: $4.14
Upside: +2,415.11%
C4 Therapeutics
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $1.55
Upside: +3,459.87%
Arvinas
Mar 31, 2021
Initiates: Outperform
Price Target: $101
Current: $9.05
Upside: +1,016.02%
Regeneron Pharmaceuticals
Jan 25, 2021
Upgrades: Outperform
Price Target: $630
Current: $602.64
Upside: +4.54%
Madrigal Pharmaceuticals
Nov 6, 2020
Maintains: Market Perform
Price Target: $119 → $124
Current: $325.27
Upside: -61.88%
bluebird bio
Nov 5, 2020
Downgrades: Market Perform
Price Target: $1,120
Current: $4.16
Upside: +26,823.08%
Gilead Sciences
Oct 29, 2020
Maintains: Market Perform
Price Target: $74 → $64
Current: $103.17
Upside: -37.97%
Jun 5, 2020
Initiates: Outperform
Price Target: $14
Current: $24.99
Upside: -43.98%
Dec 3, 2019
Downgrades: Market Perform
Price Target: $47 → $60
Current: $1.47
Upside: +3,981.63%
Mar 8, 2018
Maintains: Market Perform
Price Target: $120 → $164
Current: $2.76
Upside: +5,856.52%